Amarin Corporation PLC (AMRN) - Total Assets
Based on the latest financial reports, Amarin Corporation PLC (AMRN) holds total assets worth $645.76 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Amarin Corporation PLC - Total Assets Trend (1993–2025)
This chart illustrates how Amarin Corporation PLC's total assets have evolved over time, based on quarterly financial data. Also see Amarin Corporation PLC (AMRN) market capitalisation for the company's overall valuation and market capitalisation.
Amarin Corporation PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
Amarin Corporation PLC's total assets of $645.76 Million consist of 96.9% current assets and 3.1% non-current assets. Review how much debt does Amarin Corporation PLC carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.1% |
| Accounts Receivable | $126.83 Million | 18.9% |
| Inventory | $195.91 Million | 29.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.37 Million | 2.0% |
| Goodwill | $13.36 Million | 2.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how Amarin Corporation PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Amarin Corporation PLC stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amarin Corporation PLC's current assets represent 96.9% of total assets in 2025, an increase from 86.0% in 1993.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2025, down from 40.9% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is inventory at 29.2% of total assets.
Amarin Corporation PLC Competitors by Total Assets
Key competitors of Amarin Corporation PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
Amarin Corporation PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.48 | 3.53 | 2.69 |
| Quick Ratio | 2.46 | 2.55 | 1.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $446.37 Million | $410.65 Million | $625.54 Million |
Amarin Corporation PLC - Advanced Valuation Insights
This section examines the relationship between Amarin Corporation PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.70 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | $670.77 Million |
| Market Capitalization | $290.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Amarin Corporation PLC's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Amarin Corporation PLC's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Amarin Corporation PLC (1993–2025)
The table below shows the annual total assets of Amarin Corporation PLC from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $670.77 Million | -2.13% |
| 2024-12-31 | $685.35 Million | -17.60% |
| 2023-12-31 | $831.68 Million | -6.15% |
| 2022-12-31 | $886.18 Million | -17.03% |
| 2021-12-31 | $1.07 Billion | +10.56% |
| 2020-12-31 | $966.02 Million | +9.50% |
| 2019-12-31 | $882.21 Million | +128.72% |
| 2018-12-31 | $385.71 Million | +138.69% |
| 2017-12-31 | $161.60 Million | -3.23% |
| 2016-12-31 | $167.00 Million | -3.73% |
| 2015-12-31 | $173.46 Million | +1.38% |
| 2014-12-31 | $171.11 Million | -32.23% |
| 2013-12-31 | $252.48 Million | -18.78% |
| 2012-12-31 | $310.86 Million | +145.97% |
| 2011-12-31 | $126.38 Million | +257.34% |
| 2010-12-31 | $35.37 Million | -37.07% |
| 2009-12-31 | $56.20 Million | +53.30% |
| 2008-12-31 | $36.66 Million | -13.25% |
| 2007-12-31 | $42.25 Million | -13.46% |
| 2006-12-31 | $48.83 Million | +4.42% |
| 2005-12-31 | $46.76 Million | +97.12% |
| 2004-12-31 | $23.72 Million | -49.93% |
| 2003-12-31 | $47.38 Million | -51.43% |
| 2002-12-31 | $97.53 Million | +7.19% |
| 2001-12-31 | $90.99 Million | +87.24% |
| 2000-12-31 | $48.60 Million | +43.98% |
| 1999-12-31 | $33.75 Million | +104.56% |
| 1998-12-31 | $16.50 Million | -58.96% |
| 1997-12-31 | $40.20 Million | -10.47% |
| 1996-12-31 | $44.90 Million | +26.12% |
| 1995-12-31 | $35.60 Million | +47.11% |
| 1993-12-31 | $24.20 Million | -- |
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The compa… Read more